UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000060607 |
|---|---|
| Receipt number | R000069325 |
| Scientific Title | A registry study of chemotherapy-ineligible metastatic hormone-sensitive prostate cancer |
| Date of disclosure of the study information | 2026/03/01 |
| Last modified on | 2026/02/06 17:58:25 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
A registry study of chemotherapy-ineligible metastatic hormone-sensitive prostate cancer
Acronym
CHAMP
Scientific Title
A registry study of chemotherapy-ineligible metastatic hormone-sensitive prostate cancer
Scientific Title:Acronym
CHAMP
Region
| Japan |
Condition
Condition
metastatic hormone-sensitive prostate cancer
Classification by specialty
| Urology |
Classification by malignancy
Malignancy
Genomic information
NO
Objectives
Narrative objectives1
To investigate current treatment practices and prognoses for hormone-sensitive prostate cancer with metastases that does not undergo chemotherapy.
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
Time to CRPC-progression
Key secondary outcomes
Base
Study type
Observational
Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| Not applicable |
Gender
Male
Key inclusion criteria
1) Patients diagnosed with metastatic hormone-sensitive prostate cancer (mHSPC).
2)Patients must be 20 years of age or older at the time of consent.
3)Patients capable of oral intake.
4)Patients receiving drug therapy for mHSPC that does not include chemotherapy.
5)Cases for which written consent has been obtained from the patient to participate in this study.
Key exclusion criteria
1) Individuals without a histological diagnosis of prostate cancer.
2) Individuals with a history of malignant tumors other than prostate cancer within the past three years.
3) Individuals with severe, hospitalization-requiring, uncontrolled complications other than malignant tumors.
4) Individuals with convulsive disorders requiring anticonvulsant therapy, except those who are clinically stable or seizure-free.
5) Patients with severe hepatic impairment
Patients with a history of hypersensitivity to any component of mHSPC therapy drugs.
Patients lacking the ability or willingness to cooperate with the procedures of this study.
8) Patients deemed unsuitable for this study by the investigator.
Example: Patients participating in another clinical study (interventional study).
Target sample size
250
Research contact person
Name of lead principal investigator
| 1st name | Kohei |
| Middle name | |
| Last name | Hashimoto |
Organization
Sapporo Medical University School of Medicine
Division name
Department of Urology
Zip code
060-8543
Address
Minami 1-Jo, Nishi 16 Cho-me, Chuo-ku, Saspporo
TEL
0116112111
kohei@cj9.so-net.ne.jp
Public contact
Name of contact person
| 1st name | Kohei |
| Middle name | |
| Last name | Hashimoto |
Organization
Sapporo Medical University School of Medicine
Division name
Department of Urology
Zip code
060-8543
Address
Minami 1-Jo, Nishi 16 Cho-me, Chuo-ku, Saspporo
TEL
0116112111
Homepage URL
kohei@cj9.so-net.ne.jp
Sponsor or person
Institute
Sapporo Medical University School of Medicine
Institute
Department
Personal name
Funding Source
Organization
none
Organization
Division
Category of Funding Organization
Local Government
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Sapporo Medical University Hospital Institutional Review Board
Address
291, Minami 1-jo Nishi 16-chome Chuo-ku Sapporo, Hokkaido
Tel
01116112111
rskk@sapmed.ac.jp
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2026 | Year | 03 | Month | 01 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Enrolling by invitation
Date of protocol fixation
| 2025 | Year | 05 | Month | 01 | Day |
Date of IRB
| 2025 | Year | 05 | Month | 15 | Day |
Anticipated trial start date
| 2025 | Year | 05 | Month | 16 | Day |
Last follow-up date
| 2030 | Year | 02 | Month | 28 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
none
Management information
Registered date
| 2026 | Year | 02 | Month | 06 | Day |
Last modified on
| 2026 | Year | 02 | Month | 06 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000069325
